EcoDrugPlus

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSAMXG00000016297
Gene Symbol: CHRNB2
3 Cross references
198 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSAMXG00000018274
Gene Symbol: CHRNB4
3 Cross references
194 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5b

Ensembl ID : ENSAMXG00000026492
Gene Symbol: CHRM5B
1 Cross references
190 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSAMXG00000032056
Gene Symbol: F2R
3 Cross references
264 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSAMXG00000039666
Gene Symbol: F2R
3 Cross references
211 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSAMXG00000000760
Gene Symbol: F3
4 Cross references
171 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSAMXG00000000120
Gene Symbol: F3
3 Cross references
199 Possible Orthologues:

Coagulation Factor Vii-Like

Ensembl ID : ENSAMXG00000033258
Gene Symbol: LOC103046085
3 Cross references
203 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSAMXG00000016120
Gene Symbol: F10
1 Cross references
246 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSAMXG00000042294
Gene Symbol: CCDC6
4 Cross references
151 Possible Orthologues:

Coiled-Coil Domain-Containing Protein 6

Ensembl ID : ENSAMXG00000039127
Gene Symbol: LOC103027082
3 Cross references
208 Possible Orthologues:

Collagenase 3-Like

Ensembl ID : ENSAMXG00000006427
Gene Symbol: LOC103041846
2 Cross references
301 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).